Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)’s share price traded up 5.4% on Monday . The company traded as high as $4.95 and last traded at $4.85, with a volume of 626,967 shares changing hands. The stock had previously closed at $4.60.

A number of equities analysts recently weighed in on the company. Maxim Group reissued a “buy” rating and set a $13.00 price objective on shares of Adamis Pharmaceuticals Corporation in a report on Monday. ValuEngine raised Adamis Pharmaceuticals Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th.

The company’s market cap is $166.16 million. The company has a 50-day moving average price of $4.87 and a 200 day moving average price of $4.30.

Several institutional investors have recently modified their holdings of ADMP. First Allied Advisory Services Inc. purchased a new position in shares of Adamis Pharmaceuticals Corporation during the second quarter worth approximately $114,000. Stonebridge Capital Advisors LLC increased its position in Adamis Pharmaceuticals Corporation by 22.2% in the second quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 5,000 shares in the last quarter. Wells Fargo & Company MN bought a new position in Adamis Pharmaceuticals Corporation during the second quarter valued at about $169,000. IFP Advisors Inc increased its position in Adamis Pharmaceuticals Corporation by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock valued at $179,000 after buying an additional 32,965 shares in the last quarter. Finally, Virtu KCG Holdings LLC increased its position in Adamis Pharmaceuticals Corporation by 103.2% in the second quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock valued at $200,000 after buying an additional 19,538 shares in the last quarter. Hedge funds and other institutional investors own 11.61% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/23/adamis-pharmaceuticals-corporation-admp-trading-5-4-higher.html.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.